Table 4.
Breast cancer characteristics and HR status in the Asian cohort (full analysis set)
| Overall (N = 104) |
gBRCA1/2m-positive (N = 11) |
gBRCA1/2m-negative (N = 93) |
|
|---|---|---|---|
| Time since breast cancer diagnosis, months |
33.0 (0.5–357.5) (n = 101) |
27.1 (3.2–160.6) (n = 9) |
33.9 (0.5–357.5) (n = 92) |
| T stage at breast cancer diagnosis | |||
| T0 (T0, Tis) | 3 (2.9) | 1 (9.1) | 2 (2.2) |
| 1 (T1, T1a–c) | 19 (18.3) | 4 (36.4) | 15 (16.1) |
| 2 (T2, T2a–c) | 54 (51.9) | 3 (27.3) | 51 (54.8) |
| 3 (T3, T3a–c) | 16 (15.4) | 2 (18.2) | 14 (15.1) |
| 4 (T4, T4a–d) | 9 (8.7) | 1 (9.1) | 8 (8.6) |
| TX | 3 (2.9) | 0 | 3 (3.2) |
| N stage at breast cancer diagnosis | |||
| N0 (N0, pN0) | 37 (35.6) | 6 (54.5) | 31 (33.3) |
| N1 (all N1) | 36 (34.6) | 4 (36.4) | 32 (34.4) |
| N2 (N2, N2a–c) | 13 (12.5) | 0 | 13 (14.0) |
| N3 (N3, N3a–c) | 13 (12.5) | 1 (9.1) | 12 (12.9) |
| NX | 5 (4.8) | 0 | 5 (5.4) |
| M stage at breast cancer diagnosis | |||
| M0 (all M0) | 78 (75.0) | 8 (72.7) | 70 (75.3) |
| M1 (all M1) | 21 (20.2) | 2 (18.2) | 19 (20.4) |
| MX | 5 (4.8) | 1 (9.1) | 4 (4.3) |
| AJCC stage at breast cancer diagnosis | |||
| 0 | 4 (3.8) | 1 (9.1) | 3 (3.2) |
| I | 12 (11.5) | 2 (18.2) | 10 (10.8) |
| II | 42 (40.4) | 5 (45.5) | 37 (39.8) |
| III | 25 (24.0) | 1 (9.1) | 24 (25.8) |
| IV | 21 (20.2) | 2 (18.2) | 19 (20.4) |
| Histological type at breast cancer diagnosisa | |||
| Invasive ductal | 83 (79.8) | 10 (90.9) | 73 (78.5) |
| Invasive carcinoma NOS | 6 (5.8) | 0 | 6 (6.5) |
| Invasive lobular | 5 (4.8) | 0 | 5 (5.4) |
| Ductal carcinoma in situ | 4 (3.8) | 1 (9.1) | 3 (3.2) |
| Papillary | 1 (1.0) | 0 | 1 (1.1) |
| Tubular | 1 (1.0) | 0 | 1 (1.1) |
| Other | 4 (3.8) | 0 | 4 (4.3) |
| HR receptor status at enrollment | n = 103 | n = 11 | n = 92 |
| Estrogen receptor positive | 58 (56.3) | 5 (45.5) | 53 (57.6) |
| Progesterone receptor positive | 40 (38.8) | 4 (36.4) | 36 (39.1) |
AJCC American Joint Committee on Cancer, HR hormone receptor, NOS not otherwise specified
Values presented are median (range) or n (%).
The number of patients with available data is provided where it differs from the overall number of patients. Percentages are based on the number of patients with available data
aNo patients had lobular carcinoma in situ, mucinous, medullary, Paget’s disease of the nipple with/without invasive carcinoma, or inflammatory histological types